Cancers attributable to human papillomavirus infection

Sexual Health

Volumn 7, Issue 3, 2010, Pages 244-252

  Grulich, Andrew E ^a   Jin, Fengyi ^a,b   Conway, E Lynne ^c   Stein, Alicia N ^c   Hocking, Jane ^d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CSL LIMITED   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Australia; cervical cancer; HPV vaccine

Indexed keywords

WART VIRUS VACCINE;

ADENOSQUAMOUS CARCINOMA; ADULT; ANUS CANCER; AUSTRALIA; CANCER CONTROL; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CHLAMYDIASIS; HERPES SIMPLEX; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; MOUTH CANCER; OROPHARYNX CANCER; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PENIS CANCER; PHIMOSIS; PREVALENCE; REVIEW; SEXUAL BEHAVIOR; SMOKING; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VACCINATION; VAGINA CANCER; VULVA CANCER; WART VIRUS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; CROSS-CULTURAL COMPARISON; CROSS-SECTIONAL STUDIES; DEVELOPING COUNTRIES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PENILE NEOPLASMS; POPULATION SURVEILLANCE; SEX FACTORS; SEXUALLY TRANSMITTED DISEASES, VIRAL; UTERINE CERVICAL NEOPLASMS; VAGINAL NEOPLASMS; VAGINAL SMEARS; VULVAR NEOPLASMS; YOUNG ADULT;

EID: 77956022842     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH10020     Document Type: Review

References (65)

1. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi F, et al. A review of human carcinogens - part B: biological agents. Lancet Oncol 2009; 10: 321-322 doi:10.1016/S1470-2045(09)70096-8
2. Barr E, Sings HL. Prophylactic HPV vaccines: new interventions for cancer control. Vaccine 2008; 26: 6244-6257 doi:10.1016/j.vaccine. 2008.07.056
3. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6: 204. doi:10.1016/S1470-2045(05)70086-3 (Pubitemid 40450709)
4. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008; 26: 612-619 doi:10.1200/JCO.2007.14.1713 (Pubitemid 351264356)
5. Parkin D, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. doi:10.3322/canjclin.55.2.74
6. World Health Organisation. Cervical cancer, human papillomavirus (HPV) and HPV vaccines. Key points for policy-makers and health professionals. Geneva: WHO; 2007. Available online at: http:// whqlibdoc.who.int/hq/2008/WHO-RHR-08. 14-eng.pdf [verified May 2010].
7. Australian Institute of Health and Welfare. Cervical screening in Australia 2006-2007. Cancer Series no 47, Cat No. CAN 43. Canberra: AIHW; 2009.
8. Wain GV. Cervical cancer prevention: the saga goes on, but so much has changed! Med J Aust 2006; 185: 476-477
9. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ 2001; 164: 1017-1025 (Pubitemid 34412231)
10. Office of National Statistics. Cancer statistics registrations: registrations of cancer diagnosed in 2006, England. MB1 No. 37; 2008. Available online at: theme-health/MB1-37/MB1-37-2006.pdf [verified May 2010].
11. Chan PK, Chang AR, Yu MY, Li W-H, Chan MYM, Yeung ACM, et al. Age distribution of human papillomavirus infection and cervical neoplasia reflects caveats of cervical screening policies. Int J Cancer 2010; 126: 297-301. doi:10.1002/ijc.24731
12. Mu∼oz N, Mendez F, Posso H, Molano M, van den Brule AJC, Ronderos M, et al. Incidence, duration and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004; 190: 2077-2087 doi:10.1086/425907 (Pubitemid 39636354)
13. Franceschi S, Herrero R, Clifford G, Snijders PJF, Arslan A, Anh PTH, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006; 119: 2677-2684 doi:10.1002/ijc.22241 (Pubitemid 44691325)
14. Leinonen M, Kotaniemi-Talonen L, Anttila A, Dyba T, Tarkkanen J, Nieminen P. Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland. Int J Cancer 2008; 123: 1344-1349 doi:10.1002/ijc.23670
15. Condon J, Armstrong B, Barnes T, Zhao Y. Cancer incidence and survival for Indigenous Australians in the Northern Territory. Aust NZ J Public Health 2005; 29: 123-128 doi:10.1111/j.1467-842X.2005. tb00061.x (Pubitemid 40585233)
16. Mitchell H, Hocking J. Improvements in the protection against adenocarcinoma of the cervix from participation in cervical screening. Cancer (Cytopathology) 2003; 99: 336-341 doi:10.1002/ cncr.11835
17. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19 doi:10.1002/(SICI)1096-9896(199909)189:1 3.0.CO;2-F
18. Cogliano V. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: human Papillomaviruses [90]. Lyon, France: World Health Organisation, International Agency for Research on Cancer; 2007.
19. Brotherton JM. How much cervical cancer in Australia is vaccine preventable? A meta-analysis. Vaccine 2008; 26: 250-256 doi:10.1016/ j.vaccine.2007.10.057
20. Clifford G, Smith J, Plummer M, Mu∼oz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a metaanalysis. Br J Cancer 2003; 88: 63-73. http://www.nature.com/bjc/journal/v88/n1/abs/6600688a. html-aff1#aff1 doi:10.1038/sj.bjc.6600688 (Pubitemid 36241220)
21. Garland SM, Brotherton JML, Skinner SR, Pitts M, Saville M, Mol G, et al. Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention. Vaccine 2008; 26(Suppl. 12), M80-8. doi:10.1016/j.vaccine.2008.05.041
22. Winkelstein W. Smoking and cervical cancer: current status - a review. Am J Epidemiol 1990; 131: 945-957
23. Vessey M, Lawless M, McPherson K, Yeates D. Neoplasia of the uterine cervix and contraception: a possible adverse effect of the pill. Lancet 1983; 322: 930-934 doi:10.1016/S0140-6736(83) 90451-8
24. Benard VB, Johnson CJ, Thompson TD, Roland KB, Lai SM, Cokkinides V, et al. Examining the association between socioeconomic status and potential human papillomavirusassociated cancers. Cancer 2008; 113: 2910.
25. Chaturvedi AK, Madeleine MM, Biggar RJ, Engles EA. Risk of human papillomavirus-associated cancers among people with AIDS. J Natl Cancer Inst 2009; 101: 1120-1130 doi:10.1093/jnci/ djp205
26. Grulich A, Leeuwen Mv, Falster M, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67. doi:10.1016/S0140-6736(07)61050-2 (Pubitemid 47017468)
27. NCHECR. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia - annual Surveillance Report 2008. Sydney: National Centre in HIV Epidemiology and Clinical Research; 2009.
28. Laws P, Grayson N, Sullivan E. Australias mothers and babies 2004. Perinatal Statistics series No 18. Sydney: Australian Institute of Health and Welfare National Perinatal Statistics Unit; 2006.
29. Australian Bureau of Statistics. National Health Survey: summary of results 2004-2005. Canberra: Australian Bureau of Statistics; 2006.
30. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human papillomavirus and related cancers in world. Summary report 2009. Barcelona: WHO/ICO; 2009. Availableonline at: http://hpv2010.org/main/images/ stories/docs/HPVInformation Centre SummaryReportWorld-Feb2010.pdf [verified May 2010]
31. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124: 1626-1636 doi:10.1002/ijc.24116
32. Australian Institute of Health and Welfare and Australasian Association of Cancer Registries. Cancer in Australia: an overview, 2008. Cancer series no 46 Cat No. CAN 42. Canberra: AIHW; 2008.
33. Australian Institute of Health and Welfare. Cancer incidence data cubes, 2009. Canberra: AIHW; 2009. Available online at: www.aihw . gov.au/cancer/data/ datacubes/index.cfm [verified May 2010].
34. Condon JR, Rumbold AR, Thorn JC, O'Brien MM, Davy MJ, Zardawi I. A cluster of vulvar cancer and vulvar intraepithelial neoplasia in young Australian Indigenous women. Cancer Causes Control 2009; 20: 67-74. doi:10.1007/s10552-008-9218-6
35. Munoz N, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, et al. Impact of human papillomavirus (HPV)-6/ 11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010; 102: 325-339 doi:10.1093/jnci/ djp534
36. Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control 2009; 20: 449-57. doi:10.1007/s10552- 008-9276-9279
37. Bleeker MC, Heideman DA, Snijders PJ, Horenblas S, Dillner J, Meijer CJLM. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol 2009; 27: 141-150 doi:10.1007/s00345-008-0302-z
38. Miralles-Guri C, Bruni L, Cubilla AL, Castellsagué X, Bosch FX, de Sanjosé S. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol 2009; 62: 870-878 doi:10.1136/ jcp.2008.063149
39. Auvert B, Sobngwi-Tambekou J, Cutler E, Nieuwoudt M, Lissouba P, Puren A, et al. Effect of male circumcision on the prevalence of highrisk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis 2009; 199: 14-19 doi:10.1086/595566
40. Frisch M, Melbye M. Anal cancer. In Schottenfeld D, Fraumeni JF, Jr., editors. Cancer epidemiology and prevention. New York: Oxford University Press, Inc; 2006. pp. 830-840
41. Joseph DA, Miller JW, Wu X, Chen VW, Morris CR, Goodman MT, et al. Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer 2008; 113: 2892-2900
42. Franceschi S, De Vuyst H. Human papillomavirus vaccines and anal carcinoma. Curr Opin HIV and AIDS 2009; 4: 57-63. doi:10.1097/ COH.0b013e32831b9c81
43. Robinson D, Coupland V, Moller H. An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast England. Br J Cancer 2009; 100: 527-531 doi:10.1038/sj.bjc.6604871
44. Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009; 124: 2375-2383 doi:10.1002/ijc.24215
45. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004; 101: 270-280 doi:10.1002/cncr.20365 (Pubitemid 38890829)
46. Vajdic CM, van Leeuwen MT, Jin F, Prestage G, Medley G, Hillman RJ, et al. Anal human papillomavirus genotype diversity and co-infection in a community-based sample of homosexual men. Sex Transm Infect 2009; 85: 330-335 doi:10.1136/sti.2008.034744
47. Daling JR, Weiss NS, Hislop TG, Maden C, Coates RJ, Sherman KJ, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 1987; 317: 973-977
48. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67. doi:10.1016/S0140-6736(07)61050-2 (Pubitemid 47017468)
49. Palefsky J. Human papillomavirus-related disease in people with HIV. Curr Opin HIV and AIDS 2009; 4: 52-56 doi:10.1097/ COH.0b013e32831a7246
50. van Leeuwen MT, Vajdic CM, Middleton MG, McDonald AM, Law M, Kaldor JM, et al. Continuing declines in some but not all HIVassociated cancers in Australia after widespread use of antiretroviral therapy. AIDS 2009; 23: 2183-2190 doi:10.1097/QAD.0b013e328 331d384
51. Palefsky J. Quadrivalent HPV vaccine efficacy against anal intraepithelial neoplasia in men having sex with men. Monte Carlo: EUROGIN; 2010.
52. Anderson JS, Vajdic C, Grulich AE. Is screening for anal cancer warranted in homosexual men? Sex Health 2004; 1: 137-140 doi:10.1071/SH03019
53. Parkin DM, Louie KS, Clifford G. Burden and trends of type-specific human papillomavirus infections and related diseases in the Asia Pacific region. Vaccine 2008; 26(Suppl. 12), M1-16. doi:10.1016/ j.vaccine.2008.05.010
54. Ryerson AB, Peters ES, Coughlin SS, Chen VW, Gillison ML, Reichman ME, et al. Burden of potentially human papillomavirusassociated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer 2008; 113: 2901-2909
55. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer 2007; 110: 1429-1435 doi:10.1002/cncr.22963 (Pubitemid 47463055)
56. Frisch M, Hjalgrim H, Jaeger AB, Biggar RJ. Changing patterns of tonsillar squamous cell carcinoma in the United States. Cancer Causes Control 2000; 11: 489-95. doi:10.1023/ A:1008918223334
57. Näsman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009; 125: 362-366 doi:10.1002/ijc.24339
58. Kreimer AR, Clifford GM, Boyle P, Falaschini S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14: 467-475 doi:10.1158/1055-9965.EPI-04- 0551 (Pubitemid 40270113)
59. Termine N, Panzarella V, Falaschini S, Russo A, Matranga D, Lo Muzio L, et al. HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). Ann Oncol 2008; 19: 1681-1690 doi:10.1093/annonc/mdn372
60. Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007; 121: 1813-1820 doi:10.1002/ ijc.22851
61. DSouza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch M, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-1956 doi:10.1056/ NEJMoa065497 (Pubitemid 46740304)
62. D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 2009; 199: 1263-1269 doi:10.1086/597755
63. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct risk factor profiles for human papillomavirus type 16- positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-420 doi:10.1093/jnci/ djn025
64. Adelstein DJ, Ridge JA, Gillison ML, Chaturvedi AK, D'Souza G, Gravitt PE, et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck 2009; 31: 1393-1422 doi:10.1002/hed.21269
65. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008; 113: 3036-3046